Mabion has unveiled its updated development strategy aimed at strengthening the Company’s position as a flexible, technologically advanced CDMO, securing new service-model contracts, and developing innovative projects based on its proprietary intellectual property. The strategy is built on three pillars: technological advancement, operational excellence, and talent development.
Key Strategic Priorities for 2025–2030
Technological Leap
- Development of biosimilar monoclonal antibodies (mAbs)
- Expansion into ADCs (antibody-drug conjugates) in collaboration with strategic partners
Capacity and Efficiency Growth
- Increasing drug substance (DS) manufacturing capacity by 40–50%
- Raising overall equipment effectiveness (OEE) by 20%
- Reducing key process lead times by 20%
Stronger Organization
- Development and retention of key talent
- Building a culture of rapid decision-making
- Strengthening the Mabion brand globally
New Business Segments
- Biosimilars
- ADCs
- Bispecific and innovative biologics
- Precision handling biologics
- Veterinary biologics
Geographic Expansion
- Entry into MENA (Middle East & North Africa) markets
- Expansion in Asia
Financial Ambitions
- Reaching revenue levels in 2030 equal to 1.5× the 2021–2025 average (over PLN 70 million)
- Target EBITDA margin above 30%
A Strategy Focused on Flexibility, Technology, and Global Expansion
Mabion’s new 2025–2030 strategy aims to build one of Europe’s most flexible and technologically advanced CDMOs. The plan will increase the Company’s global visibility, expand its project portfolio, and strengthen competitiveness in the field of biologics — where cutting-edge technology, speed, and reliability are crucial.
The updated strategy assumes full focus on Drug Substance manufacturing and expansion into high-growth market segments.
Pillar 1: Technological Advancement as the Foundation of Expansion
This pillar covers both the development and production of biologics — an area in which Mabion already possesses strong expertise — and the Company’s expansion into ADCs through close collaboration with strategic partners. Mabion will be responsible for protein components, upstream and downstream processes, and analytics, enabling entry into one of the industry’s fastest-growing segments.
An important element of this pillar is the return to the MabionCD20 project — not as a biosimilar product, but as a component of an innovative ADC, opening new opportunities for intellectual property development.
Pillar 2: Operational Excellence and Scalable Capacity
Mabion aims to execute more projects in less time by improving operational scalability and efficiency.
Planned measures include:
- Installation of two new bioreactors (2,000 L and 3,000 L), increasing DS capacity by 40–50%
- Improving OEE by 20%
- Reducing critical lead times by 20% through digitalization, lean management, and elimination of bottlenecks
- Strengthening quality systems — a key priority for clients who require predictable, fast, high-quality project execution
These efforts will significantly enhance Mabion’s ability to meet growing demand for advanced biologics manufacturing.
Pillar 3: Organizational Strength and Talent Development
Mabion aims to build a future-ready organization capable of rapid growth and increasingly complex projects.
Key initiatives include:
- Development programs for leaders and specialists
- Clear career paths
- A 20% annual increase in training budgets
- Building a culture of fast response and decision-making, supported by practical use of AI tools
- Strengthening the employer brand and global CDMO market visibility through industry events, partnerships, and communication efforts
Geographic and Business Model Expansion
Mabion plans to expand into MENA and Asian markets, leveraging rising demand for technological partners in these regions.
The Company will combine:
- Traditional fee-for-service contracts, and
- Co-development models, sharing risks, costs, and potential profits with partners.
Financial Targets and Funding
The Company aims to achieve operational break-even by the end of 2026, and by 2030 increase revenues to 1.5× the 2021–2025 average, with EBITDA margins above 30%.
The strategy will be financed through:
- Equity
- Operating cash flows
- Debt financing
- EU grants
In parallel with the strategy update, Mabion revised its ESG targets for 2025–2027 to align them with the new business objectives.
Gregor Kawaletz, President & CEO of Mabion S.A., comments:
**“The new strategy sends a clear message: Mabion is accelerating. We are focusing on what creates real value for clients — technology, scalability, and a partnership-driven approach. We are entering high-growth segments and expanding capacity to execute more advanced projects, faster and with greater predictability.
The CDMO market is changing rapidly, and we intend to be among those setting the pace — not simply responding to it. This strategy strengthens our position and significantly increases the chances of securing new contracts and building Mabion into a CDMO of choice in Europe.”**
